1. What urologists need to know about ketamine‐induced uropathy: A systematic review
2. Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
3. Esketamine for treatment resistant depression;Jauhar;The British Medical Journal,2019
4. European Monitoring Centre for Drugs and Drug Addiction (2002) Report on the Risk Assessment of Ketamine in the Framework of the Joint Action on New Synthetic Drugs. European Monitoring Centre for Drugs and Drug Addiction.
5. Nash, AI , Borenstein, S , O'Hara, M , Zhang, Q , Barbreau, S , Mulhern Haughey, S , Bossie, C , Daly, E , Mathews, M , Ming, T , Denee, T , Nagda, N , Riley, D and Perry, R (2021) Treatment-resistant depression: expert consensus identified real-world experience and individualized care as considerations for novel treatments in major depressive disorder. National Network of Depression Centers Virtual Meeting.